Stimuli‐Responsive Hybrid Vesicle for Tumor Dual‐Model NIR‐II Photoacoustic and Fluorescence Imaging and Precise Radiotherapy
Source abstract
Abstract
Abstract Bioimaging guided‐radiotherapy is widely investigated as one of the mainstream cancer theranostic strategies for precision medicine. Nevertheless, background noise with “always‐on” imaging signal and inadequate tumor enrichment restrict disease diagnosis and therapy. Here, a nanogapped gold nanoparticles (AuNNPs)–silver sulfide (Ag2S) vesicle (Ve) is designed as a “biological switch” through the self‐assembly of pH‐responsive polymer thiolated polystyrene‐co‐poly(4‐vinylpyridine) grafted AuNNPs and Ag2S quantum dots (QDs). The AuNNPs–Ag2S Ve exhibits quenched NIR‐II fluorescence (FL) and enhanced photoacoustic signals initially, which can be specifically activated by an acidic environment to release Ag2S QDs and “turn on” NIR‐II FL signal in the second near‐infrared (NIR‐II, 950–1700 nm) window. Besides, the strategy of disease‐located NIR‐II imaging guided cancer therapy can remarkably enhance the therapeutic efficacy of radiotherapy, as well as minimize side effects. Such an intelligent nanoplatform with the ability of stimulus activated NIR‐II imaging guided radiotherapy shows great promise to precision biomedicine in the future.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nuclear Medicine China‐Japan Union Hospital of Jilin University Changchun 130033 P. R. China
MOE key Laboratory for Analytical Science of Food Safety and Biology College of Chemistry Fuzhou University Fuzhou 350108 P. R. China
NHC Key Laboratory of Radiobiology School of Public Health of Jilin University Changchun 130033 P. R. China
Funding
National Natural Science Foundation of China
References (28)
Show source-provided references
1. 10.1002/adma.20200321410.1002/adma.202003214 ↗
2. 10.1021/acsnano.0c0531710.1021/acsnano.0c05317 ↗
3. 10.1007/s12274-020-2992-510.1007/s12274-020-2992-5 ↗
4. 10.1039/C8CS00921J10.1039/C8CS00921J ↗
5. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
6. 10.1039/D0CC01080D10.1039/D0CC01080D ↗
7. 10.1039/D0SC00862A10.1039/D0SC00862A ↗
8. 10.1002/advs.20180180610.1002/advs.201801806 ↗
9. Wang J. · Adv. Funct. Mater. · 2020 · 30 · 201908825
10. 10.1002/anie.20190152510.1002/anie.201901525 ↗
11. 10.1039/D0CS00664E10.1039/D0CS00664E ↗
12. 10.1002/anie.20190353610.1002/anie.201903536 ↗
13. 10.1039/C9SC06567A10.1039/C9SC06567A ↗
14. 10.1021/ja909490r10.1021/ja909490r ↗
15. 10.1021/acs.nanolett.1c0019710.1021/acs.nanolett.1c00197 ↗
16. 10.1002/adma.20190151310.1002/adma.201901513 ↗
17. 10.1002/adma.20190674510.1002/adma.201906745 ↗
18. 10.1002/anie.20211370310.1002/anie.202113703 ↗
19. 10.1021/acsnano.0c0011810.1021/acsnano.0c00118 ↗
20. 10.1002/adma.20211069010.1002/adma.202110690 ↗
21. 10.1016/j.nantod.2021.10112010.1016/j.nantod.2021.101120 ↗
22. 10.1021/acsnano.0c1040710.1021/acsnano.0c10407 ↗
23. 10.1002/adom.20210023310.1002/adom.202100233 ↗
24. 10.1002/adfm.20180642910.1002/adfm.201806429 ↗
25. 10.1021/acs.accounts.9b0013610.1021/acs.accounts.9b00136 ↗
26. 10.1002/anie.20200988810.1002/anie.202009888 ↗
27. 10.1002/advs.20200258910.1002/advs.202002589 ↗
28. 10.1021/jacs.8b0939610.1021/jacs.8b09396 ↗